Wearable technology shows promise in assessing physical activity, cough in cystic fibrosis

Patients receiving treatment for cystic fibrosis wore actigraphy sensors and cough monitoring systems for the majority of a 12-week period, according to a poster presented at the North American Cystic Fibrosis Conference.

“Overall, we noted high adherence to the use of an actigraphy watch and a cough sensor monitor during this 12-week study of people with cystic fibrosis on commercial Trikafta,” Andrew T. Braun, MD, MHS, assistant professor at the University of Wisconsin School of Medicine and Public Health and director of the UW Health adult cystic fibrosis program, told Healio. Read the full story in Healio.